Showing 2411-2420 of 3153 results for "".
Take 5: Recent Developments in Systemic Therapy for Psoriasis
https://practicaldermatology.com/columns/recent-developments/take-5-recent-developments-in-systemic-therapy-for-psoriasis/22002/New data reveal noteworthy financial and clinical trends in the use of systemic agents.Natural Ingredients and Their Applications in Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/natural-ingredients-and-their-applications-in-dermatology/22022/Understanding the role of natural ingredients in therapeutic regimens may help physicians to harness these agents for maximum effect.Business Advisor: Mapping Out a Price/Benefit Value Strategy for Your Practice
https://practicaldermatology.com/topics/general-topics/business-advisor-mapping-out-a-pricebenefit-value-strategy-for-your-practice/22043/Using a Price/Benefit map is a good way for practices to set prices and plan to adapt to changing markets.Effectiveness of Early Moisturizer Use in Atopic Dermatitis Prevention
https://practicaldermatology.com/issues/novemberdecember-2025/effectiveness-of-early-moisturizer-use-in-atopic-dermatitis-prevention/48889/In the 2025 study by Simpson et al entitled “Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial,” once-daily, full-body emollient use initiated at 9 weeks of age significantly reduced the cumulative incidence of atopic dermatitis (AD) by 24 months.Apocrine Hidrocystoma of the Axilla
https://practicaldermatology.com/issues/october-2025/apocrine-hidrocystoma-of-the-axilla-an-illustrative-case-and-literature-review/39757/An Illustrative Case and Literature ReviewCutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Dermatology Recruitment in the Age of Private Equity
https://practicaldermatology.com/issues/september-2025/dermatology-recruitment-in-the-age-of-private-equity/37638/A recruiting executive offers a balanced view from the fieldComorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.Journal Club: Dupilumab and Atopic March
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Reduced